I don't usually agree with Cramer, especially in biotech, but he has made a few good calls and I think he has good connections, so I would not be suprised if he knows something???

Either way, IMGN is greatly undervalued. If the upcoming data are positive and Roche files, IMGN will be much higher. If the data are good, but not good enough, the price will probably go back to the $5 range and then back up as the phase III data mature next year. I think the high end of the analyst target range is very appropriate, $12-14 in Dec if the data are good enough for Roche to file. So, $7 upside $2 downside.